menu
    • menu
    [{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"ProBioGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Etakafusp Alpha","moa":"CD8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Asher Biotherapeutics \/ Asher Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ Asher Biotherapeutics"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etakafusp Alpha","moa":"CD8","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Asher Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etakafusp Alpha","moa":"CD8","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Asher Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etakafusp Alpha","moa":"CD8","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Asher Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Etakafusp Alpha","moa":"||CD8","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Asher Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"Etakafusp Alpha","moa":"CD8","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"Asher Biotherapeutics \/ Wellington Management Company","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Wellington Management Company"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Etakafusp Alpha","moa":"||CD8","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Asher Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Series C Financing","leadProduct":"Etakafusp Alpha","moa":"||CD8","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Asher Biotherapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Agreement","leadProduct":"Etakafusp Alpha","moa":"||CD8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ AstraZeneca","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Etakafusp Alpha","moa":"||CD8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ Amgen Inc","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AB359","moa":"CD8\/IL-2R","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Asher Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Lonza Biologics Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"AB359","moa":"CD8\/IL-2R","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ Asher Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Asher Biotherapeutics \/ Asher Biotherapeutics"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etakafusp Alfa","moa":"CD8\/IL-2R","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Asher Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Asher Biotherapeutics \/ Asher Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Asher Biotherapeutics \/ Asher Biotherapeutics"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Asher Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"AB821","moa":"IL-21 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Asher Biotherapeutics \/ Asher Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Asher Biotherapeutics"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AB821","moa":"IL-21 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Asher Biotherapeutics

    Menu

    Asher Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tarlatamab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tarlatamab + AB248 Studied In Extensive Stage Small Cell Lung Cancer

                            Details : Tarlatamab is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Small Cell Lung Carcinoma.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 25, 2025

                            Lead Product(s) : Tarlatamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB821

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Yale University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AB821 in Adult Participants with Locally Advanced or Metastatic Solid Tumors

                            Details : AB821 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            June 18, 2025

                            Lead Product(s) : AB821

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Yale University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etakafusp Alpha,Tarlatamab

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Amgen Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Asher Bio, BeiGene Collaborate on AB248, T-Cell Engager for Lung Cancer

                            Details : As part of this collaboration agreement, Amgen will sponsor a global Phase 1b study to evaluate the early efficacy of AB248 (etakafusp alfa) in combination with Imdelltra in patients with ES-SCLC.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            January 08, 2025

                            Lead Product(s) : Etakafusp Alpha,Tarlatamab

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Amgen Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etakafusp Alpha,Rilvegostomig

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Asher Bio, BeiGene Collaborate on AB248 Phase 1b/2 NSCLC Clinical Trial

                            Details : As part of this agreement, AstraZeneca will operationalize a global study of AB248 (etakafusp alfa) as a first-line treatment in combination with rilvegostomig in patients with advanced NSCLC.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            January 07, 2025

                            Lead Product(s) : Etakafusp Alpha,Rilvegostomig

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etakafusp Alpha,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : RA Capital Management

                            Deal Size : $55.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Asher Bio Closes $55 Million Series C Financing for Trials

                            Details : AB248, a novel IL-2 mutein fused to anti-CD8β antibody, is in Phase 1 trials as a CD8+ T cell selective IL-2 for cancer treatment.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            April 16, 2024

                            Lead Product(s) : Etakafusp Alpha,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : RA Capital Management

                            Deal Size : $55.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etakafusp Alpha,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Asher Bio Announces Dosing of First Patient in Phase 1a/1b Clinical Trial of AB248, a Cis-targeted IL-2 Immuno...

                            Details : AB248 is a novel CD8+ T cell selective IL-2, it selectively and potently activate CD8+ T-cells, while avoiding NK cells, which can act as pharmacological sink and contribute to toxicity, and regulatory T (Treg) cells, which are immunosuppressive.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 17, 2023

                            Lead Product(s) : Etakafusp Alpha,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etakafusp Alfa

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors

                            Details : Etakafusp Alfa is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 16, 2022

                            Lead Product(s) : Etakafusp Alfa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB821

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Asher Bio to Present New Preclinical Data for Selective Support of CAR-T Cell Therapies by Cis-Targeted IL-2 a...

                            Details : AB821, a CD8-IL21 cytokine has the potential to treat tumor types that may not be responsive to IL-2 and/or PD-1 therapy. PD-1-resistant tumors are associated with reduced memory T cell numbers and increased exhausted T cell numbers.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 03, 2022

                            Lead Product(s) : AB821

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB359

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at ...

                            Details : AB359, a CD8-targeted interleukin-2 (IL-2) immunotherapy for the treatment of chronic viral infections is potentially more tolerable and more active IL‑2-based therapy for the treatment of chronic HBV.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 21, 2022

                            Lead Product(s) : AB359

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Asher Biotherapeutics

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etakafusp Alpha

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Asher Bio to Present New Preclinical Data for CD8+ T Cell Targeted Immunotherapies, AB248 and AB821, at SITC 2...

                            Details : AB248, Asher Bio’s lead cis-targeted immunotherapy, is a novel CD8-targeted IL-2 mutein designed to selectively activate interleukein-2 (IL-2) signaling on CD8+ T cells over natural killer cells and regulatory T (Treg) cells.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 05, 2022

                            Lead Product(s) : Etakafusp Alpha

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth